1
|
Darricau M, Dou C, Kinet R, Zhu T, Zhou L, Li X, Bedel A, Claverol S, Tokarski C, Katsinelos T, McEwan WA, Zhang L, Gao R, Bourdenx M, Dehay B, Qin C, Bezard E, Planche V. Tau seeds from Alzheimer's disease brains trigger tau spread in macaques while oligomeric-Aβ mediates pathology maturation. Alzheimers Dement 2024; 20:1894-1912. [PMID: 38148705 PMCID: PMC10984505 DOI: 10.1002/alz.13604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 11/15/2023] [Accepted: 11/17/2023] [Indexed: 12/28/2023]
Abstract
INTRODUCTION The "prion-like" features of Alzheimer's disease (AD) tauopathy and its relationship with amyloid-β (Aβ) have never been experimentally studied in primates phylogenetically close to humans. METHODS We injected 17 macaques in the entorhinal cortex with nanograms of seeding-competent tau aggregates purified from AD brains or control extracts from aged-matched healthy brains, with or without intracerebroventricular co-injections of oligomeric-Aβ. RESULTS Pathological tau injection increased cerebrospinal fluid (CSF) p-tau181 concentration after 18 months. Tau pathology spreads from the entorhinal cortex to the hippocampal trisynaptic loop and the cingulate cortex, resuming the experimental progression of Braak stage I to IV. Many AD-related molecular networks were impacted by tau seeds injections regardless of Aβ injections in proteomic analyses. However, we found mature neurofibrillary tangles, increased CSF total-tau concentration, and pre- and postsynaptic degeneration only in Aβ co-injected macaques. DISCUSSION Oligomeric-Aβ mediates the maturation of tau pathology and its neuronal toxicity in macaques but not its initial spreading. HIGHLIGHTS This study supports the "prion-like" properties of misfolded tau extracted from AD brains. This study empirically validates the Braak staging in an anthropomorphic brain. This study highlights the role of oligomeric Aβ in driving the maturation and toxicity of tau pathology. This work establishes a novel animal model of early sporadic AD that is closer to the human pathology.
Collapse
Affiliation(s)
- Morgane Darricau
- Univ. Bordeaux, CNRSInstitut des Maladies NeurodégénérativesBordeauxFrance
| | - Changsong Dou
- NHC Key Laboratory of Human Disease Comparative MedicineBeijing Engineering Research Center for Experimental Animal Models of Human Critical DiseasesNational Center for Technology and Innovation of Animal ModelInstitute of Laboratory Animal SciencesChinese Academy of Medical Sciences (CAMS)BeijingP.R. China
| | - Remi Kinet
- Univ. Bordeaux, CNRSInstitut des Maladies NeurodégénérativesBordeauxFrance
| | - Tao Zhu
- NHC Key Laboratory of Human Disease Comparative MedicineBeijing Engineering Research Center for Experimental Animal Models of Human Critical DiseasesNational Center for Technology and Innovation of Animal ModelInstitute of Laboratory Animal SciencesChinese Academy of Medical Sciences (CAMS)BeijingP.R. China
| | - Li Zhou
- NHC Key Laboratory of Human Disease Comparative MedicineBeijing Engineering Research Center for Experimental Animal Models of Human Critical DiseasesNational Center for Technology and Innovation of Animal ModelInstitute of Laboratory Animal SciencesChinese Academy of Medical Sciences (CAMS)BeijingP.R. China
| | - Xianglei Li
- NHC Key Laboratory of Human Disease Comparative MedicineBeijing Engineering Research Center for Experimental Animal Models of Human Critical DiseasesNational Center for Technology and Innovation of Animal ModelInstitute of Laboratory Animal SciencesChinese Academy of Medical Sciences (CAMS)BeijingP.R. China
| | - Aurélie Bedel
- CHU de BordeauxService de biochimie, BordeauxUniv. BordeauxBordeauxFrance
| | | | | | - Taxiarchis Katsinelos
- UK Dementia Research InstituteDepartment of Clinical NeurosciencesUniversity of CambridgeCambridgeUK
| | - William A. McEwan
- UK Dementia Research InstituteDepartment of Clinical NeurosciencesUniversity of CambridgeCambridgeUK
| | - Ling Zhang
- NHC Key Laboratory of Human Disease Comparative MedicineBeijing Engineering Research Center for Experimental Animal Models of Human Critical DiseasesNational Center for Technology and Innovation of Animal ModelInstitute of Laboratory Animal SciencesChinese Academy of Medical Sciences (CAMS)BeijingP.R. China
| | - Ran Gao
- NHC Key Laboratory of Human Disease Comparative MedicineBeijing Engineering Research Center for Experimental Animal Models of Human Critical DiseasesNational Center for Technology and Innovation of Animal ModelInstitute of Laboratory Animal SciencesChinese Academy of Medical Sciences (CAMS)BeijingP.R. China
| | - Mathieu Bourdenx
- UK Dementia Research InstituteUCL Queen Square Institute of NeurologyLondonUK
| | - Benjamin Dehay
- Univ. Bordeaux, CNRSInstitut des Maladies NeurodégénérativesBordeauxFrance
| | - Chuan Qin
- NHC Key Laboratory of Human Disease Comparative MedicineBeijing Engineering Research Center for Experimental Animal Models of Human Critical DiseasesNational Center for Technology and Innovation of Animal ModelInstitute of Laboratory Animal SciencesChinese Academy of Medical Sciences (CAMS)BeijingP.R. China
- Changping National laboratory (CPNL)BeijingChina
| | - Erwan Bezard
- Univ. Bordeaux, CNRSInstitut des Maladies NeurodégénérativesBordeauxFrance
- Motac NeuroscienceFloiracFrance
| | - Vincent Planche
- Univ. Bordeaux, CNRSInstitut des Maladies NeurodégénérativesBordeauxFrance
- CHU de Bordeaux, Pôle de Neurosciences CliniquesCentre Mémoire de Ressources et de RechercheBordeauxFrance
| |
Collapse
|
2
|
Thomas JL, Nilaver BI, Lomniczi A, Brown DI, Appleman ML, Kohama SG, Urbanski HF. Pathological Markers of Alzheimer's Disease and Related Dementia in the Rhesus Macaque Amygdala. J Alzheimers Dis Rep 2024; 8:25-32. [PMID: 38229831 PMCID: PMC10790150 DOI: 10.3233/adr-230184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 12/12/2023] [Indexed: 01/18/2024] Open
Abstract
Rhesus macaques develop amyloid-β (Aβ) plaques during old age, but it is unclear how extensively they express other pathological hallmarks of dementia. Here we used immunohistochemistry to examine expression of phosphorylated tau (pTau) protein and cytoplasmic inclusions of TAR DNA binding protein 43 kDa (TDP-43) within the amygdala of young and old males, and also in old surgically-menopausal females that were maintained on regular or obesogenic diets. Only one animal, a 23-year-old female, showed pTau expression and none showed TDP-43 inclusions. What genetic and/or environmental factors protect macaques from expressing more severe human neuro-pathologies remains an interesting unresolved question.
Collapse
Affiliation(s)
- Jeremy L. Thomas
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR, USA
| | - Benjamin I. Nilaver
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR, USA
| | - Alejandro Lomniczi
- Department of Physiology & Biophysics, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Donald I. Brown
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR, USA
- Facultad de Ciencias, Universidad de Valparaíso, Valparaíso, Chile
| | - Maria-Luisa Appleman
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR, USA
| | - Steven G. Kohama
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR, USA
| | - Henryk F. Urbanski
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR, USA
- Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, OR, USA
| |
Collapse
|
3
|
Darricau M, Katsinelos T, Raschella F, Milekovic T, Crochemore L, Li Q, Courtine G, McEwan WA, Dehay B, Bezard E, Planche V. Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates. Brain 2023; 146:2524-2534. [PMID: 36382344 PMCID: PMC10232263 DOI: 10.1093/brain/awac428] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2022] [Revised: 10/26/2022] [Accepted: 11/04/2022] [Indexed: 11/17/2022] Open
Abstract
Progressive supranuclear palsy is a primary tauopathy affecting both neurons and glia and is responsible for both motor and cognitive symptoms. Recently, it has been suggested that progressive supranuclear palsy tauopathy may spread in the brain from cell to cell in a 'prion-like' manner. However, direct experimental evidence of this phenomenon, and its consequences on brain functions, is still lacking in primates. In this study, we first derived sarkosyl-insoluble tau fractions from post-mortem brains of patients with progressive supranuclear palsy. We also isolated the same fraction from age-matched control brains. Compared to control extracts, the in vitro characterization of progressive supranuclear palsy-tau fractions demonstrated a high seeding activity in P301S-tau expressing cells, displaying after incubation abnormally phosphorylated (AT8- and AT100-positivity), misfolded, filamentous (pentameric formyl thiophene acetic acid positive) and sarkosyl-insoluble tau. We bilaterally injected two male rhesus macaques in the supranigral area with this fraction of progressive supranuclear palsy-tau proteopathic seeds, and two other macaques with the control fraction. The quantitative analysis of kinematic features revealed that progressive supranuclear palsy-tau injected macaques exhibited symptoms suggestive of parkinsonism as early as 6 months after injection, remaining present until euthanasia at 18 months. An object retrieval task showed the progressive appearance of a significant dysexecutive syndrome in progressive supranuclear palsy-tau injected macaques compared to controls. We found AT8-positive staining and 4R-tau inclusions only in progressive supranuclear palsy-tau injected macaques. Characteristic pathological hallmarks of progressive supranuclear palsy, including globose and neurofibrillary tangles, tufted astrocytes and coiled bodies, were found close to the injection sites but also in connected brain regions that are known to be affected in progressive supranuclear palsy (striatum, pallidum, thalamus). Interestingly, while glial AT8-positive lesions were the most frequent near the injection site, we found mainly neuronal inclusions in the remote brain area, consistent with a neuronal transsynaptic spreading of the disease. Our results demonstrate that progressive supranuclear palsy patient-derived tau aggregates can induce motor and behavioural impairments in non-human primates related to the prion-like seeding and spreading of typical pathological progressive supranuclear palsy lesions. This pilot study paves the way for supporting progressive supranuclear palsy-tau injected macaque as a relevant animal model to accelerate drug development targeting this rare and fatal neurodegenerative disease.
Collapse
Affiliation(s)
- Morgane Darricau
- University of Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - Taxiarchis Katsinelos
- UK Dementia Research Institute, Department of Clinical Neurosciences, University of Cambridge, CB2 0AH Cambridge, UK
| | - Flavio Raschella
- Swiss Federal Institute of Technology (EPFL), CH-1011 Lausanne, Switzerland
- Defitech Center for Interventional Neurotherapies (NeuroRestore), CH-1011 Lausanne, Switzerland
- Centre Hospitalier Universitaire Vaudois (CHUV), CH-1011 Lausanne, Switzerland
| | - Tomislav Milekovic
- Swiss Federal Institute of Technology (EPFL), CH-1011 Lausanne, Switzerland
- Defitech Center for Interventional Neurotherapies (NeuroRestore), CH-1011 Lausanne, Switzerland
- Centre Hospitalier Universitaire Vaudois (CHUV), CH-1011 Lausanne, Switzerland
| | - Louis Crochemore
- University of Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - Qin Li
- Motac Neuroscience, F-33000 Bordeaux, France
| | - Grégoire Courtine
- Swiss Federal Institute of Technology (EPFL), CH-1011 Lausanne, Switzerland
- Defitech Center for Interventional Neurotherapies (NeuroRestore), CH-1011 Lausanne, Switzerland
- Centre Hospitalier Universitaire Vaudois (CHUV), CH-1011 Lausanne, Switzerland
| | - William A McEwan
- UK Dementia Research Institute, Department of Clinical Neurosciences, University of Cambridge, CB2 0AH Cambridge, UK
| | - Benjamin Dehay
- University of Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - Erwan Bezard
- University of Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- Motac Neuroscience, F-33000 Bordeaux, France
| | - Vincent Planche
- University of Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CHU de Bordeaux, Pôle de Neurosciences Cliniques, Centre Mémoire de Ressources et de Recherche, F-33000 Bordeaux, France
| |
Collapse
|
4
|
I F. The unique neuropathological vulnerability of the human brain to aging. Ageing Res Rev 2023; 87:101916. [PMID: 36990284 DOI: 10.1016/j.arr.2023.101916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 03/19/2023] [Accepted: 03/21/2023] [Indexed: 03/30/2023]
Abstract
Alzheimer's disease (AD)-related neurofibrillary tangles (NFT), argyrophilic grain disease (AGD), aging-related tau astrogliopathy (ARTAG), limbic predominant TDP-43 proteinopathy (LATE), and amygdala-predominant Lewy body disease (LBD) are proteinopathies that, together with hippocampal sclerosis, progressively appear in the elderly affecting from 50% to 99% of individuals aged 80 years, depending on the disease. These disorders usually converge on the same subject and associate with additive cognitive impairment. Abnormal Tau, TDP-43, and α-synuclein pathologies progress following a pattern consistent with an active cell-to-cell transmission and abnormal protein processing in the host cell. However, cell vulnerability and transmission pathways are specific for each disorder, albeit abnormal proteins may co-localize in particular neurons. All these alterations are unique or highly prevalent in humans. They all affect, at first, the archicortex and paleocortex to extend at later stages to the neocortex and other regions of the telencephalon. These observations show that the phylogenetically oldest areas of the human cerebral cortex and amygdala are not designed to cope with the lifespan of actual humans. New strategies aimed at reducing the functional overload of the human telencephalon, including optimization of dream repair mechanisms and implementation of artificial circuit devices to surrogate specific brain functions, appear promising.
Collapse
Affiliation(s)
- Ferrer I
- Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona, Spain; Emeritus Researcher of the Bellvitge Institute of Biomedical Research (IDIBELL), Barcelona, Spain; Biomedical Research Network of Neurodegenerative Diseases (CIBERNED), Barcelona, Spain; Institute of Neurosciences, University of Barcelona, Barcelona, Spain; Hospitalet de Llobregat, Barcelona, Spain.
| |
Collapse
|